Preventive capacity of allergen immunotherapy on the natural history of allergy

Journal of Preventive Medicine and Hygiene

Volumn 54, Issue 2, 2013, Pages 71-74

  Incorvaia, C ^a  

^a ICP Hospital   (Italy)

Author keywords

Allergen immunotherapy; Mechanisms of action; Preventive capacity

Indexed keywords

ALLERGEN; GAMMA INTERFERON; HYMENOPTERA VENOM; IMMUNOGLOBULIN E; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 32; INTERLEUKIN 4; INTERLEUKIN 5;

ALLERGEN IMMUNOTHERAPY; ALLERGIC RHINITIS; ALLERGY; ASTHMA; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG MECHANISM; HISTORY; HUMAN; HYMENOPTERA; IMMUNOTHERAPY; INSECT ALLERGY; INSECT STING; PHENOTYPE; PRIMARY PREVENTION; RESPIRATORY TRACT ALLERGY; REVIEW; T LYMPHOCYTE;

EID: 84888308732     PISSN: 11212233     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Bousquet J, Lockey R, Malling HJ (eds). Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO Position Paper. J Allergy Clin Immunol 1998;102:558-62.
2. Incorvaia C, Frati F. One century of allergen-specific immunotherapy for respiratory allergy. Immunotherapy 2011;3:629-35.
3. Calderon MA, Casale TB, Togias A, et al. Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond. J Allergy Clin Immunol 2011;127:30-8.
4. Committee on Safety in Medicine. CSM update: desensitizing vaccines. BMJ 1986;293:948.
5. Lockey RF, Benedikt LM, Turkeltaub PC, et al. Fatalities from immunotherapy (IT) and skin testing (ST). J Allergy Clin Immunol 1987;79:660-77.
6. Scadding GK, Brostoff J. Low dose sublingual therapy in patients with allergic rhinitis due to house dust mite. Clin Allergy 1986;6;483-91.
7. Canonica GW, Bousquet J, Casale T, et al. World Allergy Organization position paper on sublingual immunotherapy. Allergy 2009;64(Suppl 91):1-59.
8. Compalati E, Passalacqua G, Bonini M, et al. The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis. Allergy 2009;64:1570-9.
9. Radulovic S, Calderon MA, Wilson D, et al. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev 2010;(12):CD002893.
10. Bilo BM, Rueff F, Mosbech H, et al; EAACI Interest Group on Insect Venom Hypersensitivity. Diagnosis of Hymenoptera venom allergy. Allergy 2005;60:1339-49.
11. Boyle RJ, Elremeli M, Hockenhull J, et al. Venom immunotherapy for preventing allergic reactions to insect stings. Cochrane Database Syst Rev 2012;(10):CD008838.
12. Incorvaia C, Frati F, Dell'Albani I, et al. Safety of Hymenoptera venom immunotherapy: a systematic review. Expert Opin Pharmacother. 2011;12:2527-32.
13. Bonifazi F, Jutel M, Bilo BM, et al; EAACI Interest Group on Insect Venom Hypersensitivity. Prevention and treatment of Hymenoptera venom allergy: guidelines for clinical practice. Allergy 2005;60:1459-70.
14. Rueff F, Wenderoth A, Przybilla B. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses. J Allergy Clin Immunol 2001;108:1027-32.
15. Bonadonna P, Zanotti R, Muller U. Mastocytosis and insect venom allergy. Curr Opin Allergy Clin Immunol 2010;10:347-53.
16. Gonzalez-de-Olano D, Alvarez-Twose I, Vega A, et al. Venom immunotherapy in patients with mastocytosis and hymenoptera venom anaphylaxis. Immunotherapy 2011;3:637-51.
17. Boulay ME, Morin A, Laprise C, et al. Asthma and rhinitis: what is the relationship? Curr Opin Allergy Clin Immunol 2012;12:449-54.
18. Niggemann B, Jacobsen L, Dreborg S, et al. Five-year followup on the PAT study: specific immunotherapy and long-term prevention of asthma in children. Allergy 2006;61:855-9.
19. Jacobsen L, Niggemann B, Dreborg S, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up of the PAT study. Allergy; 2007;62:943-8.
20. Di Rienzo V, Marcucci F, Puccinelli P, et al. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin Exp Allergy 2003;33:206-10.
21. Madonini E, Agostinis F, Barra R, et al. Long-term and preventive effects of sublingual allergen-specific immunotherapy: a retrospective, multicentric study. Int J Immunopathol Pharmacol 2003;16:73-9.
22. Marogna M, Tomassetti D, Bernasconi A, et al. Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study. Ann Allergy Asthma Immunol 2008;101:206-11.
23. Des Roches A, Paradis L, Menardo JL, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol 1997;99:450-53.
24. Eng PA, Reinhold M, Gnehm HP. Long-term efficacy of preseasonal grass pollen immunotherapy in children. Allergy 2002;57:306-12.
25. Pajno GB, Barberio G, De Luca F, et al. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 2001;31:1392-97.
26. Purello-D'Ambrosio F, Gangemi S, Merendino RA, et al. Prevention of new sensitizations in monsensitized subjects submitted to specific immunotherapy or not. A retrospective study. Clin Exp Allergy 2001;31:1295-302.
27. Marogna M, Spadolini I, Massolo A, et al. Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. J Allergy Clin Immunol 2010;126:969-75.
28. Holt PG. Primary prevention by early intervention with specific immunotherapy. Drugs Today 2008;44 (suppl B):75-7.
29. Senti G, Johansen P, Kundig TM. Intralymphatic immunotherapy. Curr Opin Allergy Clin Immunol 2009;9:537-43.
30. Senti G, Johansen P, Kundig TM. Intralymphatic immunotherapy: from the rationale to human applications. Curr Top Microbiol Immunol 2011;352:71-84.
31. Majori S, Baldo V, Poli A, et al. Immunity to poliovirus among children and the elderly in north-east Italy. J Prev Med Hyg 2006;47:12-5.
32. Adkinson NF, Sobotka AK, Lichtenstein LM. Evaluation of the quantity and affinity of human IgG "blocking" antibodies. J Immunol 1979;122:965-72.
33. Leynadier F, Lambin P, Murrieta M, Dry J. Blocking antibodies to inhalant allergens and asthma. Allerg Immunol (Paris) 1991;23:341-7.
34. Golden DB, Addison BI, Gadde J, et al. Prospective observations on stopping prolonged venom immunotherapy. J Allergy Clin Immunol 1989;84:162-7.
35. Cady CT, Powell MS, Harbeck RJ, et al. IgG antibodies produced during allergen immunotherapy mediate inhibition of basophil activation via a mechanism involving both FcgammaRIIA and FcgammaRIIB. Immunol Lett 2010;130:57-65.
36. Soyer OU, Akdis M, Akdis CA. Mechanisms of subcutaneous allergen immunotherapy. Immunol Allergy Clin North Am 2011;31:175-90.
37. Yacoub MR, Colombo G, Marcucci F, et al. Effects of sublingual immunotherapy on allergic inflammation: an update. Inflamm Allergy Drug Targets 2012;11:285-91.
38. Bohle B, Kinaciyan T, Gerstmayr M, et al. Sublingual immunotherapy induces IL-10 producing T regulatory cells, allergen specific T-cell tolerance, and immune deviation. J Allergy Clin Immunol 2007;120:7070-13.
39. Soyka MB, Holzmann D, Akdis CA. Regulatory cells in allergen-specific immunotherapy. Immunotherapy 2012;4:389-96.
40. Valenta R, Campana R, Marth K, et al. Allergen-specific immunotherapy: from therapeutic vaccines to prophylactic approaches. J Intern Med 2012;272:144-57.
41. Canonica GW, Baena-Cagani CE, Compalati E, et al. 100 years of immunotherapy: the Monaco Charter. Under the high patronage of His Serene Highness Prince Albert II of Monaco. Int Arch Allergy Immunol 2012;160:346-49.